Abstract

One of the major goals in immunology research is to understand the regulatory mechanisms that underpin the rapid switch on/off of robust and efficient effector (Teffs) or regulatory (Tregs) T-cell responses. Understanding the molecular mechanisms underlying the regulation of such responses is critical for the development of effective therapies. T-cell activation involves the engagement of T-cell receptor and co-stimulatory signals, but the subsequent recruitment of serine/threonine-specific protein Kinase C-theta (PKC-θ) to the immunological synapse (IS) is instrumental for the formation of signaling complexes, which ultimately lead to a transcriptional network in T cells. Recent studies demonstrated that major differences between Teffs and Tregs occurred at the IS where its formation induces altered signaling pathways in Tregs. These pathways are characterized by reduced recruitment of PKC-θ, suggesting that PKC-θ inhibits Tregs suppressive function in a negative feedback loop. As the balance of Teffs and Tregs has been shown to be central in several diseases, it was not surprising that some studies revealed that PKC-θ plays a major role in the regulation of this balance. This review will examine recent knowledge on the role of PKC-θ in T-cell transcriptional responses and how this protein can impact on the function of both Tregs and Teffs.

Highlights

  • Current global health challenges demand more effective and safer therapies to dampen undesired immune responses as in autoimmune diseases, inflammation, and transplant rejection, and aim at boosting desired responses such as in cancer and infections

  • Strong T-cell activation involves the engagement of T-cell receptor (TCR) and co-stimulatory signals

  • PKC-θ is the first PKC family member described to be recruited to the immunological synapse (IS) [5] and it plays an integral role in activating a range of signaling cascades that results in a transcriptional network in T cells

Read more

Summary

Introduction

Current global health challenges demand more effective and safer therapies to dampen undesired immune responses as in autoimmune diseases, inflammation, and transplant rejection, and aim at boosting desired responses such as in cancer and infections. Pseudosubstrate is unlocked from kinase domain, allowing subsequent catalytic activation of PKC-θ and its downstream signaling functions required for T-cell survival, proliferation, and homeostasis [25]. Upon the TCR/CD28 activation, PKC-θ phosphorylates membrane-associated guanylate kinase (MAGUK) domain-containing protein 1 (CARMA1) on its serine residues, resulting in the recruitment of B-cell lymphoma/ leukemia 10 (BCL10) and mucosa-associated lymphoid tissue 1 (MALT1) to form an active CARMA1–BCL10–MALT1 signaling complex.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call